Development of a MID for the 1-minute Sit-to-stand Test
Development of a Minimal Important Difference for the 1-minute Sit-to-stand Test
1 other identifier
interventional
105
1 country
1
Brief Summary
The purpose of this study is to determine the minimal important difference (MID) for the 1-minute-sit-to-stand-test (STST) with an anchor-based method.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Apr 2016
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 10, 2016
CompletedFirst Posted
Study publicly available on registry
March 15, 2016
CompletedStudy Start
First participant enrolled
April 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2017
CompletedFebruary 15, 2018
February 1, 2018
1.7 years
March 10, 2016
February 14, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
MID of the 1-minute-STST
Change of maximum 1-minute sit-to-stand repititions
21 days
Secondary Outcomes (2)
6-minute-walk distance
21 days
CRQ Score
21 days
Study Arms (1)
Pulmonary rehabilitation
OTHERmultimodal pulmonary Rehabilitation program (3 weeks Duration)
Interventions
Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
Eligibility Criteria
You may qualify if:
- Patients with COPD (GOLD-Stage II to IV)
- Ability to stand-up and walk
- written informed consent
You may not qualify if:
- orthopaedic or other comorbidities that prevent patients from performing the STST, 6MWT or exercise Training
- acute exacerbation
- heart failure, acute coronary syndrome
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Schön Klinik Berchtesgadener Landlead
- AstraZenecacollaborator
Study Sites (1)
Berchtesgardener Land
Schönau am Königssee, Bavaria, 83471, Germany
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Klaus Kenn, Prof. Dr.
Schoen Klinik BGL
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Prof. Dr. Klaus Kenn
Study Record Dates
First Submitted
March 10, 2016
First Posted
March 15, 2016
Study Start
April 1, 2016
Primary Completion
December 1, 2017
Study Completion
December 1, 2017
Last Updated
February 15, 2018
Record last verified: 2018-02
Data Sharing
- IPD Sharing
- Will not share